This article is more than 5 years old. Information may no longer be current.

VIDEO: Anti-CD47 fusion protein well tolerated by patients with solid tumors, non-Hodgkin lymphoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Sophia Randolph, MD, PhD, chief medical officer at Alexo Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about ALX148.

The anti-CD47 fusion protein is in development for treatment of patients with advanced solid tumors, as well as those with non-Hodgkin lymphoma.

“CD47 is among the most interesting novel targets being explored in oncology today because of its central role in mediating immune response against cancer,” Randolph told HemOnc Today.

At ASCO, researchers presented data from a first-in-human trial of ALX148 that showed the agent is well tolerated. Investigators did not reach a maximum tolerated dose with the agent as monotherapy or as part of combination treatment.

The maximum administered dose will be used in the next phase of the trial, which will include expansion cohorts designed to assess ALX148 in combination with pembrolizumab (Keytruda, Merck), rituximab (Rituxan; Genentech, Biogen) or trastuzumab (Herceptin, Genentech) in specific tumor types.

Randolph also highlighted the key three ways that ALX148 differs from other CD47-targeted agents.